Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-7,877
Closed -$221K 279
2016
Q4
$221K Sell
7,877
-1,096
-12% -$30.8K 0.03% 234
2016
Q3
$246K Sell
8,973
-1,636
-15% -$44.9K 0.04% 223
2016
Q2
$231K Buy
10,609
+1,606
+18% +$35K 0.04% 224
2016
Q1
$201K Buy
9,003
+676
+8% +$15.1K 0.04% 214
2015
Q4
$230K Buy
8,327
+463
+6% +$12.8K 0.04% 210
2015
Q3
$203K Buy
+7,864
New +$203K 0.04% 232
2014
Q4
Sell
-11,430
Closed -$260K 313
2014
Q3
$260K Buy
+11,430
New +$260K 0.05% 249
2014
Q1
Sell
-8,720
Closed -$208K 343
2013
Q4
$208K Sell
8,720
-8,680
-50% -$207K 0.05% 292
2013
Q3
$372K Sell
17,400
-17,400
-50% -$372K 0.09% 217
2013
Q2
$692K Buy
+34,800
New +$692K 0.04% 222

Other funds holding QGENF

CIBC Bank USA's QGENF Position: Q1 2017 in Review

CIBC Bank USA sold out of QIAGEN NV (QGENF) in Q1 2017, closing a stake of 7,877 shares — an estimated $221K sold.

CIBC Bank USA first reported a position in QGENF in Q2 2013 and held it in 10 quarters. The position peaked at $692K in Q2 2013. 6 funds tracked by Wall St. Rank hold QGENF as of Q1 2017.

  • CIBC Bank USA reported no remaining QIAGEN NV position as of Q1 2017 after selling out during the quarter.
  • CIBC Bank USA sold 7,877 QIAGEN NV shares in Q1 2017, an estimated $221K.
  • CIBC Bank USA first reported a position in QIAGEN NV in Q2 2013 and held it in 10 quarters.
  • CIBC Bank USA's QIAGEN NV position peaked at $692K in Q2 2013.
  • 6 funds tracked by Wall St. Rank held QIAGEN NV as of Q1 2017.

Based on CIBC Bank USA's 13F filing for Q1 2017, filed 13 Apr 2017.